How shorted is Inhibikase Therapeutics, Inc. right now?

14.49% of Inhibikase Therapeutics, Inc.'s (IKT) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.

What does this number include?

FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.

Why does it only update twice a month?

US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.

Which funds are short?

US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.

How shorted is Inhibikase Therapeutics, Inc.?

More shorted than 90% of the 2,877 ranked US companies

14.49%

of shares outstanding reported short · settlement date 31 Jul 2026

vs previous report: +0.66
5 reports (~10 weeks): +1.09

Embed this chart

Paste this snippet to embed the interactive chart. It updates with each FINRA report and keeps the source attribution. Preview

<iframe src="https://howshorted.com/embed/us/ikt/" width="100%" height="430" style="border:0" loading="lazy" title="Inhibikase Therapeutics, Inc. short interest chart"></iframe>
<p>Source: FINRA data compiled by <a href="https://howshorted.com/us/company/ikt/">howshorted.com</a></p>

Cite this page

Short position data for Inhibikase Therapeutics, Inc.: FINRA, compiled by howshorted.com, settlement date 31 Jul 2026. https://howshorted.com/us/company/ikt/

History

Settlement date	Short %	Change
31 Jul 2026	14.49%	+0.66
15 Jul 2026	13.83%	−0.88
30 Jun 2026	14.71%	+0.40
15 Jun 2026	14.31%	+0.29
29 May 2026	14.02%	+0.62
15 May 2026	13.40%	−0.22
30 Apr 2026	13.62%	+0.15
15 Apr 2026	13.47%	+0.40
31 Mar 2026	13.07%	−8.26
13 Mar 2026	21.33%	−0.01
27 Feb 2026	21.34%	+7.32
13 Feb 2026	14.02%	+2.26
30 Jan 2026	11.76%	+1.65
15 Jan 2026	10.11%	+1.13
31 Dec 2025	8.98%	+1.87
15 Dec 2025	7.11%	+1.60
28 Nov 2025	5.51%	+1.41
14 Nov 2025	4.10%	+0.04
31 Oct 2025	4.06%	−0.23
15 Oct 2025	4.29%	−0.38
30 Sep 2025	4.67%	+0.40
15 Sep 2025	4.27%	−0.19
29 Aug 2025	4.46%	+0.04
15 Aug 2025	4.42%	+0.34
31 Jul 2025	4.08%	–

Frequently asked questions

How shorted is Inhibikase Therapeutics, Inc. right now?: 14.49% of Inhibikase Therapeutics, Inc.'s (IKT) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.
What does this number include?: FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.
Why does it only update twice a month?: US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.
Which funds are short?: US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.